Table 1.
Clinical information on MAFLD patients and healthy controls.
| clinical pathological indicators | MAFLD patients |
healthy controls |
||||
|---|---|---|---|---|---|---|
| N = 92 | % | N = 74 | % | P | ||
| Age (year) | 57.25 ± 12.72 | 35.91 ± 16.66 | <0.01* | |||
| Sex | female | 40 | 43.5 | 48 | 64.9 | 0.01# |
| male | 52 | 56.5 | 26 | 35.1 | ||
| BMI(kg/m2) | 26.49 ± 3.85 | 22.12 ± 3.03 | 0.01 | |||
| WHR | 0.95 ± 0.07 | 0.81 ± 0.07 | 0.01 | |||
| ALT (U/L) | 39.04 ± 50.18 | 19.81 ± 11.20 | 0.01 | |||
| AST (U/L) | 31.86 ± 42.26 | 24.65 ± 6.55 | 0.39 | |||
| GGT(U/L) | 41.80 ± 43.34 | 24.08 ± 17.86 | 0.05 | |||
| TG (mmol/L) | 2.50 ± 2.22 | 1.03 ± 0.53 | 0.01 | |||
| TBIL(umol/L) | 15.41 ± 6.02 | 15.01 ± 5.48 | 0.76 | |||
| DB(umol/L) | 2.48 ± 1.55 | 2.55 ± 0.79 | 0.73 | |||
| FPG (mmol/L) | 9.36 ± 4.87 | 5.14 ± 0.47 | 0.01 | |||
| HDL-C(mmol/L) | 1.10 ± 0.27 | 1.57 ± 0.29 | 0.01 | |||
| LDL-C(mmol/L) | 3.08 ± 1.10 | 2.99 ± 0.66 | 0.62 | |||
| HbA1C(%) | 8.93 ± 2.05 | 5.53 ± 0.39 | 0.01 | |||
| Neutrophils (*109/L) | 4.05 ± 1.05 | 3.12 ± 0.99 | 0.01 | |||
Continuous variables expressed as mean ± SD; *Independent t-test, #Pearson chi-square test or Fisher's exact test. Abbreviation: HC: healthy controls; BMI: Body Mass Index; WHR: Waist-hip ratio; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT:γ-glutamyl transferase; TG: Triglycerides; TBIL: total bilirubin; DB: Direct bilirubin; FPG: fasting plasma glucose; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; HbA1C: hemoglobin A1c.